clofibric acid has been researched along with fenofibric acid in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (25.00) | 18.7374 |
| 1990's | 10 (41.67) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 2 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Chapman, JM; Kliewer, SA; Koble, CS; Lehmann, JM; Lewis, MC; Moore, LB; Plunket, KD; Sundseth, SS; Willson, TM; Wilson, JG; Winegar, DA; Wu, Z | 1 |
| Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX | 1 |
| Conte Camerino, D; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Piemontese, L; Pierno, S; Pochetti, G; Tortorella, P | 1 |
| Brinkjost, T; Ehrt, C; Koch, O | 1 |
| Aarsland, A; Berge, RK | 1 |
| Galteau, MM; Guéguen, R; Leroy, P; Liu, HF; Magdalou, J; Nicolas, A; Siest, G; Vincent-Viry, M | 1 |
| Fournel, S; Magdalou, J; Pinon, P; Siest, G | 1 |
| Beaumont, JL; Beaumont, V; Buxtorf, JC; Carcone, B; Doucet, F; Edouard, L; Jacotot, B | 1 |
| Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J | 1 |
| Franceschini, G; Paoletti, R; Sirtori, CR | 1 |
| Santafé Oroz, J; Segarra Domènech, J | 1 |
| Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K | 1 |
| Cornu-Chagnon, MC; Dupont, H; Edgar, A | 1 |
| Caldwell, J; Grubb, N; Weil, A | 1 |
| Walsh, KB; Wang, C | 1 |
| Cuniberti, LA; Masnatta, LD; Rey, RH; Werba, JP | 1 |
| Kockx, M; Kooistra, T; Princen, HM | 1 |
| Derudas, B; Gervois, PP; Gonzalez, FJ; Kockx, M; Kooistra, T; Peters, JM; Poulain, P; Princen, HM; Staels, B | 1 |
| Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
| Mikhailidis, DP; Wierzbicki, AS; Wray, R | 1 |
| Cariou, B; Costet, P; Jarnoux, AL; Kourimate, S; Krempf, M; Langhi, C; Le May, C; Nguyen, P; Ouguerram, K; Zaïr, Y | 1 |
| Jacobson, TA | 1 |
| Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J | 1 |
| Fukuhara, H; Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T | 1 |
3 review(s) available for clofibric acid and fenofibric acid
| Article | Year |
|---|---|
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Gemfibrozil; Glycosaminoglycans; Humans; Ion Exchange Resins; Lipoproteins; Nicotinic Acids; Pentanoic Acids; Probucol | 1983 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Insulin Resistance; Liver Diseases; Obesity; Pancreatitis; Pregnancy; Pregnancy Complications | 2001 |
Myopathy with statin-fibrate combination therapy: clinical considerations.
Topics: Clofibric Acid; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents | 2009 |
4 trial(s) available for clofibric acid and fenofibric acid
| Article | Year |
|---|---|
Effects of several lipid-lowering drugs on skin total and esterified cholesterol.
Topics: Cholesterol Esters; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Probucol; Random Allocation; Skin | 1986 |
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Propionates; Time Factors | 1985 |
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship | 1983 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates | 1982 |
17 other study(ies) available for clofibric acid and fenofibric acid
| Article | Year |
|---|---|
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
Topics: Animals; Butyrates; DNA-Binding Proteins; Fenofibrate; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Mice; Nuclear Proteins; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Zinc Fingers | 1999 |
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides | 2007 |
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Topics: Animals; Cell Line, Tumor; Chloride Channels; Chlorides; Clofibric Acid; Crystallography, X-Ray; Drug Discovery; Electric Conductivity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Male; Models, Molecular; Molecular Conformation; Muscle, Skeletal; Muscular Diseases; PPAR alpha; PPAR gamma; Propionates; Rats; Rats, Wistar; Rest; Stereoisomerism; Substrate Specificity | 2009 |
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.
Topics: Binding Sites; Chemistry, Pharmaceutical; Drug Design; Models, Chemical; Proteins | 2016 |
Peroxisome proliferating sulphur- and oxy-substituted fatty acid analogues are activated to acyl coenzyme A thioesters.
Topics: Animals; Clofibric Acid; Enzyme Activation; Fatty Acids; Fenofibrate; Liver; Male; Microbodies; Oxides; Palmitoyl Coenzyme A; Palmitoyl-CoA Hydrolase; Rats; Rats, Inbred Strains; Sulfides; Sulfoxides | 1991 |
Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic?
Topics: Adult; Chromatography, High Pressure Liquid; Clofibric Acid; Female; Fenofibrate; Glucuronates; Humans; Hypolipidemic Agents; Male; Middle Aged; Molecular Structure; Polymorphism, Genetic; Reference Values | 1991 |
Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents.
Topics: Animals; Biphenyl Compounds; Body Weight; Butyrophenones; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Enzyme Induction; Epoxide Hydrolases; Fenofibrate; gamma-Glutamyltransferase; Glucuronosyltransferase; Hypolipidemic Agents; Lipids; Liver; Male; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1987 |
Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes.
Topics: Animals; Cells, Cultured; Clofibric Acid; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Fenofibrate; Fibric Acids; Guinea Pigs; Humans; Liver; Male; Mass Spectrometry; Microbodies; Mixed Function Oxygenases; Palmitoyl Coenzyme A; Rats; Rats, Wistar; Species Specificity; Time Factors; Tumor Cells, Cultured | 1995 |
Studies on the in vitro reactivity of clofibryl and fenofibryl glucuronides. Evidence for protein binding via a Schiff's base mechanism.
Topics: Buffers; Clofibric Acid; Fenofibrate; Glucuronates; Humans; In Vitro Techniques; Protein Binding; Serum Albumin; Solutions | 1993 |
Effect of chloride channel blockers on the cardiac CFTR chloride and L-type calcium currents.
Topics: Animals; Anthracenes; Calcium; Calcium Channel Blockers; Chloride Channels; Chlorides; Clofibric Acid; Colforsin; Cystic Fibrosis Transmembrane Conductance Regulator; Fenofibrate; Gemfibrozil; Glycolates; Guinea Pigs; Ion Transport; Mice; Myocardium; ortho-Aminobenzoates; Patch-Clamp Techniques; Stilbenes | 1996 |
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
Topics: Bezafibrate; Calibration; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Reproducibility of Results; Sensitivity and Specificity | 1996 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Topics: Animals; Cells, Cultured; Clofibrate; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Fibric Acids; Fibrinogen; Gene Expression Regulation; Hypolipidemic Agents; Kinetics; Liver; Male; Mice; Mice, Knockout; Peroxisome Proliferators; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Transcription, Genetic; Triglycerides | 1999 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Topics: Anticholesteremic Agents; Cell Line, Tumor; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Furin; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Hydrocarbons, Fluorinated; Hyperlipoproteinemia Type II; Lipid Metabolism; Liver X Receptors; Orphan Nuclear Receptors; PPAR alpha; Pravastatin; Promoter Regions, Genetic; Proprotein Convertase 5; Proprotein Convertase 9; Proprotein Convertases; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Serine Endopeptidases; Sulfonamides; Up-Regulation | 2008 |
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics | 2009 |
A simple and sensitive method for the determination of fibric acids in the liver by liquid chromatography.
Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Liver; Male; PPAR alpha; Rats; Rats, Wistar; Reproducibility of Results; RNA, Messenger | 2014 |